Alex Lyakhovich

List of Publications by Citations

48 papers	1,147 citations	20 h-index	32 g-index
57 ext. papers	1,328 ext. citations	7.7 avg, IF	4.65 L-index

#	Paper	IF	Citations
48	Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. *EMBO Journal*, **2007**, 26, 1340-51	13	107
47	Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. *Oncogene*, **2014**, 33, 165-72	9.2	88
46	Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. *Cancer Research*, **2002**, 62, 2115-24	10.1	69
45	miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. *Cell Death and Disease*, **2017**, 8, e3141	9.8	60
44	Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 202-9	6.1	55
43	Vitamin D and prostate cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 76, 125-34	5.1	49
42	Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. *Cancer Letters*, **2006**, 232, 99-106	9.9	41
41	Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. *Molecular and Cellular Biology*, **2003**, 23, 2463-75	4.8	40
40	The interplay between autophagy and tumorigenesis: exploiting autophagy as a means of anticancer therapy. *Biological Reviews*, **2018**, 93, 152-165	13.5	37
39	Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. *Oncoscience*, **2014**, 1, 272-282	0.8	37
38	DNA damage response and resistance of cancer stem cells. *Cancer Letters*, **2020**, 474, 106-117	9.9	36
37	RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response. *Oncogene*, **2004**, 23, 3097-106	9.2	35
36	Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. *Biochemical Pharmacology*, **2013**, 85, 234-44	6	34
35	Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 1716341	6.7	34
34	Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition. *Cancer Letters*, **2017**, 384, 60-69	9.9	30
33	Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells. *Molecular Cancer Research*, **2010**, 8, 46-56	6.6	26
32	Vitamin D induced up-regulation of keratinocyte growth factor (FGF-7/KGF) in MCF-7 human breast cancer cells. *Biochemical and Biophysical Research Communications*, **2000**, 273, 675-80	3.4	26

31	IL-6, IL-8, MMP-2, MMP-9 are overexpressed in Fanconi anemia cells through a NF-B/TNF- dependent mechanism. *Molecular Carcinogenesis*, **2015**, 54, 1686-99	5	25
30	Mitochondrial dysfunction and potential anticancer therapy. *Medicinal Research Reviews*, **2017**, 37, 1275-1298	11.4	24
29	Common Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer. *Molecular and Cellular Proteomics*, **2019**, 18, 231-244	7.6	24
28	Reactive Oxygen Species-Mediated Autophagy Defines the Fate of Cancer Stem Cells. *Antioxidants and Redox Signaling*, **2018**, 28, 1066-1079	8.4	18
27	New roads to FA/BRCA pathway: H2AX. *Cell Cycle*, **2007**, 6, 1019-23	4.7	18
26	Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs. *Current Medicinal Chemistry*, **2015**, 22, 3040-53	4.3	18
25	ROMO1 regulates RedOx states and serves as an inducer of NF-B-driven EMT factors in Fanconi anemia. *Cancer Letters*, **2015**, 361, 33-8	9.9	17
24	Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells. *Biochemical Pharmacology*, **2014**, 87, 312-20	6	17
23	Fanconi anemia protein FANCD2 inhibits TRF1 polyADP-ribosylation through tankyrase1-dependent manner. *Genome Integrity*, **2011**, 2, 4	0.8	17
22	Damaged mitochondria in Fanconi anemia - an isolated event or a general phenomenon?. *Oncoscience*, **2014**, 1, 287-95	0.8	17
21	Impaired mitophagy in Fanconi anemia is dependent on mitochondrial fission. *Oncotarget*, **2016**, 7, 58065-58074	5.5	17
20	Evolutionary computation techniques for multiple sequence alignment		15
19	The position of the amino group on the benzene ring is critical for mesalamines improvement of replication fidelity. *Inflammatory Bowel Diseases*, **2010**, 16, 576-82	4.5	14
18	Damaged mitochondria and overproduction of ROS in Fanconi anemia cells. *Rare Diseases (Austin, Tex)*, **2013**, 1, e24048		11
17	Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	11
16	FANCD2 depletion sensitizes cancer cells repopulation ability in vitro. *Cancer Letters*, **2007**, 256, 186-95	9.9	10
15	Activation of glycogenolysis and glycolysis in breast cancer stem cell models. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165886	6.9	7
14	Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities. *Medicinal Chemistry*, **2011**, 7, 92-8	1.8	7

13	Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. *Inflammation Research*, **2021**, 70, 159-170	7.2	6
12	Mitochondrial dysfunction in DDR-related cancer predisposition syndromes. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1865, 184-9	11.2	5
11	Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance. *FEBS Journal*, **2021**, 288, 2184-2202	5.7	5
10	Mitoprotective Clinical Strategies in Type 2 Diabetes and Fanconi Anemia Patients: Suggestions for Clinical Management of Mitochondrial Dysfunction. *Antioxidants*, **2020**, 9,	7.1	4
9	A DIGE-based approach to study interacting proteins. *Journal of Proteomics*, **2007**, 70, 693-5		4
8	Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. *Translational Research*, **2021**, 229, 135-141	11	4
7	Triphenilphosphonium Analogs of Chloramphenicol as Dual-Acting Antimicrobial and Antiproliferating Agents. *Antibiotics*, **2021**, 10,	4.9	3
6	Geometric quantization of N=2,D=3 superanyon. *Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics*, **1998**, 423, 293-300	4.2	2
5	Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management. *Redox Biology*, **2021**, 40, 101860	11.3	2
4	Quick two-dimensional differential in gel electrophoresis-based method to determine length and secondary structures of telomeric DNA. *Analytical Biochemistry*, **2009**, 384, 356-8	3.1	1
3	Mitigating the pro-oxidant state and melanogenesis of Retinitis pigmentosa: by counteracting mitochondrial dysfunction. *Cellular and Molecular Life Sciences*, **2021**, 78, 7491-7503	10.3	1
2	Identification of metabolic changes leading to cancer susceptibility in Fanconi anemia cells. *Cancer Letters*, **2021**, 503, 185-196	9.9	1
1	Targeting cancer stem cells with antibiotics inducing mitochondrial dysfunction as an alternative anticancer therapy.. *Biochemical Pharmacology*, **2022**, 198, 114966	6	1